Gene profiling suggests a common evolution of bladder cancer subtypes

BMC Medical Genomics

Bin T Teh²  David Petillo³  Zhongfa Zhang³  Donna E Hansel¹ 

[1] Department of Pathology, University of California at San Diego, 9500 Gilman Drive, MC 0612, La Jolla, CA 92093, USA;Duke-NUS Graduate Medical School, Singapore, Singapore;Van Andel Research Institute, Grand Rapids, MI, USA

关键词: Subtype;    Squamous;    Urothelial;    Bladder cancer;    Gene expression profiling;   

Others  :  1091722
DOI  :  10.1186/1755-8794-6-42

 received in 2013-06-06, accepted in 2013-10-11,  发布年份 2013

【 摘 要 】

Background

Bladder cancer exists as several distinct subtypes, including urothelial carcinoma (UCa), squamous cell carcinoma (SCCa), adenocarcinoma and small cell carcinoma. These entities, despite showing distinct morphology and clinical behavior, arise from the urothelial lining and are often accompanied by similar precursor/in situ findings. The relationship between these subtypes has not been explored in detail.

Methods

We compared gene expression analysis of the two most common subtypes of bladder cancer, UCa (n = 10) and SCCa (n = 9), with an additional comparison to normal urothelium from non-cancer patients (n = 8) using Affymetrix GeneChip Human genome arrays (Affymetrix, Santa Clara, CA). The results were stratified by supervised and unsupervised clustering analysis, as well as by overall fold change in gene expression.

Results

When compared to normal urothelium, UCa showed differential expression of 155 genes using a 5-fold cut-off. Examples of differentially regulated genes included topoisomerases, cancer-related transcription factors and cell cycle mediators. A second comparison of normal urothelium to SCCa showed differential expression of 503 genes, many of which were related to squamous-specific morphology (desmosomal complex, intermediate filaments present within squamous epithelium, squamous cornifying proteins, and molecules upregulated in squamous carcinomas from other anatomic sites). When compared, 137 genes were commonly dysregulated in both UCa and SCCa as compared to normal urothelium. All dysregulated genes in UCa were shared in common with SCCa, with the exception of only 18 genes. Supervised clustering analysis yielded correct classification of lesions in 26/27 (96%) of cases and unsupervised clustering analysis yielded correct classification in 25/27 (92.6%) of cases.

Conclusions

The results from this analysis suggest that bladder SCCa shares a significant number of gene expression changes with conventional UCa, but also demonstrates an additional set of alterations that is unique to this entity that defines the squamous phenotype. The similarity in deregulated gene products suggests that SCCa may be a much more closely related entity at the molecular level to conventional UCa than previously hypothesized.

【 授权许可】

   
2013 Hansel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Wu XR: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005, 5:713-725.
• [2]Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, et al.: ICUD-EAU international consultation on bladder cancer 2012: pathology. Eur Urol 2013, 63:16-35.
• [3]Lagwinski N, Thomas A, Stephenson AJ, Campbell S, Hoschar AP, El-Gabry E, Dreicer R, Hansel DE: Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 2007, 31:1777-1787.
• [4]Eble JN, Sauter G, Epstein JI, Sesterhenn IA: Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004.
• [5]Ewis AA, El-Samman E, Ali N, Kajimoto K, Shinohara Y, Ishikawa M, Kanayama HO, Baba Y: Gene expression profile in squamous cell carcinoma of the urinary bladder using complementary deoxyribonucleic acid microarray. Urol Oncol 2007, 25:120-127.
• [6]Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, et al.: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005, 11:4044-4055.
• [7]Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C: Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002, 62:6973-6980.
• [8]Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE: Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997, 57:4111-4117.
• [9]Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE: Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics 2010, 3:58. BioMed Central Full Text
• [10]Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
• [11]Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15.
• [12]Paradis E, Claude J, Strimmer K: APE: analyses of Phylogenetics and Evolution in R language. Bioinformatics 2004, 20:289-290.
• [13]Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, et al.: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002, 94:1320-1329.
• [14]Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, et al.: The investigational aurora kinase a inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 2013, 19:1717-1728.
• [15]Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al.: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008, 3:e1651.
• [16]Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH, et al.: The forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 2006, 66:2153-2161.
• [17]Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH, et al.: FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009, 4:e4849.
• [18]Waseem A, Ali M, Odell EW, Fortune F, Teh MT: Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol 2010, 46:536-542.
• [19]Nakano I, Paucar AA, Bajpai R, Dougherty JD, Zewail A, Kelly TK, Kim KJ, Ou J, Groszer M, Imura T, et al.: Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 2005, 170:413-427.
• [20]Gudmundsson KO, Thorsteinsson L, Sigurjonsson OE, Keller JR, Olafsson K, Egeland T, Gudmundsson S, Rafson T: Gene expression analysis of hematopoietic progenitor cells identifies Dlg7 as a potential stem cell gene. Stem Cells 2007, 25:1498-1506.
• [21]Dougherty JD, Garcia AD, Nakano I, Livingstone M, Norris B, Polakiewicz R, Wexler EM, Sofroniew MW, Kornblum HL, Geschwind DH: PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci 2005, 25:10773-10785.
• [22]Badenhorst P: Tramtrack controls glial number and identity in the drosophila embryonic CNS. Development 2001, 128:4093-4101.
• [23]Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X: Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 2008, 14:2236-2244.
• [24]Saban MR, Hellmich HL, Simpson C, Davis CA, Lang ML, Ihnat MA, O’Donnell MA, Wu XR, Saban R: Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins. BMC Cancer 2007, 7:204. BioMed Central Full Text
• [25]Tanaka F, Yamamoto K, Suzuki S, Inoue H, Tsurumaru M, Kajiyama Y, Kato H, Igaki H, Furuta K, Fujita H, et al.: Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut 2010, 59:1457-1464.
• [26]Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML: Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol 2012, 30:428-433.
• [27]Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
• [28]Bryan RT, Tselepis C: Cadherin switching and bladder cancer. J Urol 2010, 184:423-431.
• [29]Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, et al.: Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006, 175:2048-2053. discussion 2053
• [30]Nishiyama H, Habuchi T, Watanabe J, Teramukai S, Tada H, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, et al.: Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990–2000 in Japan. Eur Urol 2004, 45:176-181.
• [31]Debbagh A, Bennani S, Hafiani M, el Mrini M, Benjelloun S: Epidermoid carcinoma of the bladder. Apropos of 14 cases. Ann Urol (Paris) 1997, 31:199-203.
• [32]Johnson DE, Schoenwald MB, Ayala AG, Miller LS: Squamous cell carcinoma of the bladder. J Urol 1976, 115:542-544.
• [33]Scosyrev E, Yao J, Messing E: Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 2009, 73:822-827.
• [34]Rundle JS, Hart AJ, McGeorge A, Smith JS, Malcolm AJ, Smith PM: Squamous cell carcinoma of bladder. A review of 114 patients. Br J Urol 1982, 54:522-526.
• [35]Khaled HM, Hamza MR, Mansour O, Gaafar R, Zaghloul MS: A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur J Cancer 2000, 36(Suppl 2):34-37.
• [36]Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, et al.: Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005, 166:1533-1539.